The Pharma Data

AUGUST 5, 2020

ASCLEPIOS I and II demonstrate the efficacy and safety of ofatumumab and its potential to become a first-choice treatment option that offers RMS patients the flexibility as they continue to live their lives,” said Krishnan Ramanathan, Neuroscience Global Program Head at Novartis. Showed a relative risk reduction of 34% ( P =.002)

Trials 52

Trials Medicine Production Containment 52

The Pharma Data

OCTOBER 29, 2021

Novartis blazoned moment that the US Food and Drug Administration (FDA) approved Scemblix ® (asciminib) for the treatment of habitual myeloid leukemia (CML) in two distinct suggestions. Scemblix is presently available for croakers to define to applicable cases in the US. Scemblix nearly doubled the MMR ratevs. sites/www.novartis.us/files/scemblix.pdf.

FDA Approval 52

FDA Approval Trials Drugs Production 52

The Pharma Data

AUGUST 29, 2020

Basel, August 29, 2020 — Novartis today announced new Phase II data for LNP023, an investigational oral treatment for paroxysmal nocturnal hemoglobinuria (PNH), presented at the virtually held 2020 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting.

Containment 52

Containment Production Development Medicine 52

Delveinsight

JANUARY 28, 2021

Iterum Therapeutics presents new drug application to FDA for Oral Sulopenem. They were astonished to discover that the gut bacteria exhibited enhanced L-tyrosine metabolism, resulting in a byproduct known as p-cresol sulfate (PCS).

Bacteria 52

Bacteria Trials Drugs Clinical Trials 52

Roots Analysis

FEBRUARY 22, 2022

Notable examples of such players, include Amgen (US), GlaxoSmithKline (UK), and Novartis (UK). Further, the device developers are collaborating with digital health companies for integration of drug delivery devices with mobile applications. Partnership Activity Focused on a Diverse Range of Autoinjector Combination Products.

Drug Delivery 52

Drug Delivery Production Marketing Development 52

Drug Discovery World

NOVEMBER 9, 2023

Gail Calvert, Field Application Scientist, Sartorius UK, on: ‘Leveraging integrated and advanced technologies for successful cell line development’. Characterisation of novel biotherapeutics This session will begin with chairperson’s remarks from Christian Graf, PhD, Fellow, Scientific Office, Novartis TRD Biologics.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Delveinsight

AUGUST 13, 2020

In October 2019, GSK filed a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking an additional indication for Trelegy Ellipta for the treatment of asthma in adults. Rate of severe asthma exacerbations was reduced by 23% (p=0.0076) over 52 weeks of treatment with BDP/FF/G vs BDP/FF.

Antibody 40

Antibody Medicine Trials Development 40